Evidence map›Paper›PMID 27638854›Full record

ArticleJournal of the renin-angiotensin-aldosterone system : JRAAS2016

Overexpression of angiotensinogen downregulates aquaporin 1 expression via modulation of Nrf2-HO-1 pathway in renal proximal tubular cells of transgenic mice.

Shiao-Ying Chang, Chao-Sheng Lo, Xin-Ping Zhao, Min-Chun Liao, Isabelle Chenier, Richard Bouley, Julie R Ingelfinger, John Sd Chan, Shao-Ling Zhang

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Shiao-Ying ChangCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.
Chao-Sheng LoCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.
Xin-Ping ZhaoCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.
Min-Chun LiaoCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.
Isabelle ChenierCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.
Richard BouleyDivision of Nephology, Massachusetts General Hospital and Harvard Medical School, USA.
Julie R IngelfingerPediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, USA.
John Sd ChanCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.
Shao-Ling ZhangCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada shao.ling.zhang@umontreal.ca.
Centre Hospitalier de l’Université de Montréal · CAHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe aimed to examine the regulation of aquaporin 1 expression in an angiotensinogen transgenic mouse model, focusing on underlying mechanisms.

methodsMale transgenic mice overexpressing rat angiotensinogen in their renal proximal tubular cells (RPTCs) and rat immortalised RPTCs stably transfected with rat angiotensinogen cDNA were used.

resultsAngiotensinogen-transgenic mice developed hypertension and nephropathy, changes that were either partially or completely attenuated by treatment with losartan or dual renin-angiotensin system blockade (losartan and perindopril), respectively, while hydralazine prevented hypertension but not nephropathy. Decreased expression of aquaporin 1 and heme oxygenase-1 and increased expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and sodium-hydrogen exchanger 3 were observed in RPTCs of angiotensinogen-transgenic mice and in angiotensinogen-transfected immortalised RPTCs. These parameters were normalised by dual renin-angiotensin system blockade. Both in vivo and in vitro studies identified a novel mechanism in which angiotensinogen overexpression in RPTCs enhances the cytosolic accumulation of Nrf2 via the phosphorylation of pGSK3β Y216. Consequently, lower intranuclear Nrf2 levels are less efficient to trigger heme oxygenase-1 expression as a defence mechanism, which subsequently diminishes aquaporin 1 expression in RPTCs.

conclusionsAngiotensinogen-mediated downregulation of aquaporin 1 and Nrf2 signalling may play an important role in intrarenal renin-angiotensin system-induced hypertension and kidney injury.

Indexed as

Down-RegulationSignal TransductionAngiotensinogenAnimalsAquaporin 1beta CateninCell LineExtracellular Matrix ProteinsGlycogen Synthase Kinase 3 betaHeme Oxygenase-1ImmunohistochemistryKelch-Like ECH-Associated Protein 1Kidney Tubules, ProximalMice, TransgenicModels, BiologicalNF-E2-Related Factor 2AngiotensinogenAquaporin 1beta CateninExtracellular Matrix ProteinsGlycogen Synthase Kinase 3 betaHeme Oxygenase-1Keap1 protein, mouseKelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseNF-E2-Related Factor 2Slc9a3 protein, ratSodium-Hydrogen Exchanger 3Sodium-Hydrogen ExchangersAquaporin-1hypertensionintrarenal renin–angiotensin systemkidney injuryNrf2

Identifiers

PMID27638854
PMCPMC5843896
OpenAlexW2519873748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.